ECG
ABCL icon

EPIQ Capital Group’s AbCellera Biologics ABCL Stock Holding History

EPIQ Capital Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-86,291
Closed -$224K – 80
2024
Q3 		$224K Hold
86,291
– – 0.06% 64
2024
Q2 		$255K Hold
86,291
– – 0.09% 54
2024
Q1 		$391K Hold
86,291
– – 0.16% 39
2023
Q4 		$493K Hold
86,291
– – 0.22% 29
2023
Q3 		$397K Hold
86,291
– – 0.21% 34
2023
Q2 		$557K Hold
86,291
– – 0.28% 27
2023
Q1 		$651K Hold
86,291
– – 0.33% 23
2022
Q4 		$874K Hold
86,291
– – 0.48% 19
2022
Q3 		$853K Sell
86,291
-23,756
-22% -$261K 0.42% 20
2022
Q2 		$1.17M Buy
110,047
+18,847
+21% +$160K 0.46% 21
2022
Q1 		$889K Sell
91,200
-1,158
-1% -$11K 0.24% 25
2021
Q4 		$1.32M Sell
92,358
-50,612
-35% -$768K 0.23% 24
2021
Q3 		$2.87M Buy
+142,970
New +$2.53M 0.3% 16

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EPIQ Capital Group's ABCL Position: Q4 2024 in Review

EPIQ Capital Group sold out of AbCellera Biologics (ABCL) in Q4 2024, closing a stake of 86,291 shares — an estimated $224K sold.

EPIQ Capital Group first reported a position in ABCL in Q3 2021 and held it in 13 quarters. The position peaked at $2.87M in Q3 2021. 146 funds tracked by Wall St. Rank hold ABCL as of Q4 2024.

  • EPIQ Capital Group reported no remaining AbCellera Biologics position as of Q4 2024 after selling out during the quarter.
  • EPIQ Capital Group sold 86,291 AbCellera Biologics shares in Q4 2024, an estimated $224K.
  • EPIQ Capital Group first reported a position in AbCellera Biologics in Q3 2021 and held it in 13 quarters.
  • EPIQ Capital Group's AbCellera Biologics position peaked at $2.87M in Q3 2021.
  • 146 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2024.

Based on EPIQ Capital Group's 13F filing for Q4 2024, filed 7 Feb 2025.